An Open Randomised Cross-over Study on Granisetron Versus Ondansetron in the Prevention of Acute Emesis Induced by Moderate Dose Cisplatin-containing Regimens

European Journal of Cancer

Volumn 32, Issue 1, 1996, Pages 82-85

  Martoni, A ^a,c   Angelelli, B ^a   Guaraldi, M ^a   Strocchi, E ^b   Pannuti, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Associazione Nazionale Tumori   (Italy)

^c Dipartimen to di Scienze Mediche Veterinarie   (Italy)

Author keywords

Anti emetic therapy; Granisetron; Ondansetron

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; GRANISETRON; METHOTREXATE; NAVELBINE; ONDANSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ACUTE DISEASE; ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; CROSS-OVER STUDIES; FEMALE; GRANISETRON; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ONDANSETRON; VOMITING;

EID: 0029915122     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00519-6     Document Type: Article

References (13)

1. Cabeddu LX, Hoffmann IS, Fuenmayor NT, et al. Efficacy of Ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990, 322, 810-816.
2. Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990, 322, 816-821.
3. Chevallier B on behalf of the Granisetron Study Group. Efficacy and safety of Granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 1990, 26, Suppl. 1, s33-s36.
4. Andrews PLR. The pharmacologic profile of Granisetron (Kytril). Sem Oncol 1994, 21, Suppl. 5, 5-7.
5. Kamanabrou D on behalf of the Granisetron Study Group. Intravenous Granisetron - establishing the optimal dose. Eur J Cancer 1990, 26, Suppl. 1, s6-s11.
6. Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989, 25, Suppl. 1, s21-s24.
7. Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992, 10, 1969-1975.
8. Machin D, Campbell MJ. Statistical Tables for the Design of Clinical Trials. Oxford, Blackwell Scientific, 1987.
9. Dixon WJ. BMDP Statistical Software - Rel 7. Los Angeles, California, University of California Press, 1992.
10. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol 1991, 2, 107-114.
11. Jantunen IT, Muhonen TT, Kataja VV, et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy. A randomised study. Eur J Cancer 1993, 29A, 1669-1672.
12. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of Granisetron and Ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994, 30A, 1083-1088.
13. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994, 51, 113-118.